Bli medlem
Bli medlem

Du är här

2016-08-31

Merus N.V. : Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that the Company will
participate in the following upcoming investor conferences:

* Ton Logtenberg, CEO, will present at the 2016 Credit Suisse Antibody Day on
Wednesday, September 7 at 2:40 PM ET at Credit Suisse's offices at One
Madison Avenue in New York City.
* Management will participate in investor meetings at Citi's 11th Annual
Biotech Conference on Thursday, September 8 at the Mandarin Oriental in
Boston.

A live webcast of the Credit Suisse presentation will be available on the
Investor page of the Company's website. An archived presentation will be
available for 90 days.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such
as long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in
Europe as a potential treatment for HER2-expressing solid tumors. Merus'
second bispecific antibody candidate, MCLA-117, is being developed as a
potential treatment for acute myeloid leukemia. The Company also has a
pipeline of proprietary bispecific antibody candidates in preclinical
development, including MCLA-158, which is designed to bind to cancer stem
cells and is being developed as a potential treatment for colorectal cancer
and other solid tumors, and Biclonics® designed to bind to various
combinations of immunomodulatory molecules, including PD-1 and PD-L1.

Contacts:

Merus N.V.
Shelley Margetson - s.margetson@merus.nl
+31 (0)30 253 8800

Argot Partners
Kimberly Minarovich - kimberly@argotpartners.com
1-212-600-1902

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.